Search

Displaying results 2741 - 2750 of 8696 in total
  1. Target

    Antiviral innate immune response receptor RIG-I

    go.drugbank.com/bio_entities/BE0012418
    TargetHumans

    May play important roles in granulocyte production and differentiation, bacterial phagocytosis and in the regulation of cell migration … Innate immune receptor that senses cytoplasmic viral nucleic acids and activates a downstream signaling cascade leading to the production of type I interferons and pro-inflammatory cytokines (PubMed:15208624

    Polypeptides: Antiviral innate immune response receptor RIG-ISynonyms: RIG-I-like receptor 1
  2. Target

    Tumor necrosis factor receptor superfamily member 13C

    go.drugbank.com/bio_entities/BE0018598
    TargetHumans

    B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. Promotes the survival of mature B-cells and the B-cell response

    Polypeptides: Tumor necrosis factor receptor superfamily member 13CSynonyms: BAFF receptor, BLyS receptor 3
  3. Target

    Tumor necrosis factor receptor superfamily member 12A

    go.drugbank.com/bio_entities/BE0020009
    TargetHumans

    Receptor for TNFSF12/TWEAK. Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins

    Polypeptides: Tumor necrosis factor receptor superfamily member 12ASynonyms: Tweak-receptor
  4. Target

    Acetylcholine receptor subunit alpha-type acr-16

    go.drugbank.com/bio_entities/BE0027703
    TargetCaenorhabditis elegans

    A subunit of the levamisole-insensitive nicotinic receptor.

    Polypeptides: Acetylcholine receptor subunit alpha-type acr-16
  5. Drug

    Belinostat

    go.drugbank.com/drugs/DB05015
    ApprovedInvestigational

    It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. … The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Thymidine

    go.drugbank.com/drugs/DB04485
    ApprovedInvestigational

    Thymidine is a naturally occurring deoxyribonucleoside that is a crucial component of the DNA salvage pathway and a building block for DNA synthesis. … [A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the

  7. Drug

    Famotidine

    go.drugbank.com/drugs/DB00927
    ApprovedInvestigational

    [L11166] While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.[L11142] … [L11166] Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory

    Mixtures: POLYSILANE MAX RASA PEPPERMINTCategories: Drugs for Acid Related Disorders, Cytochrome P-450 CYP1A2 Inhibitors
  8. Drug

    Lesinurad

    go.drugbank.com/drugs/DB11560
    ApprovedWithdrawn

    Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. … It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  9. Drug

    Vaborbactam

    go.drugbank.com/drugs/DB12107
    ApprovedInvestigational

    Vabomere consists of vaborbactam and [Meropenem] for intravenous administration. … In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI).

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Tanaproget

    go.drugbank.com/drugs/DB04787
    Experimental

    An analog of tanaproget, 4-fluoropropyltanaproget (18F), has been developed as a radiotracer for imaging of the PR in positron emission tomography. … Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals.